Astec LifeSciences Limited — Others, 29-07-2025: Copy of Newspaper Publication

Astec LifeSciences has announced a board meeting on July 28, 2025, where it approved the financial results for the quarter ended June 30, 2025, following Audit Committee review. The company reported a consolidated total income from operations of ₹91.59 Cr and a consolidated net loss of ₹33.03 Cr for the quarter. Separately, the Board also approved a rights issue, offering 1 fully paid-up equity share for every 7 shares held, at an issue price of ₹890.00 per share. This rights issue, for up to 28,01,673 shares, aims to raise a maximum of ₹249.35 Cr.